Загрузка...
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as v...
Сохранить в:
| Опубликовано в: : | BMC Ophthalmol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6288953/ https://ncbi.nlm.nih.gov/pubmed/30537942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-018-0978-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|